Many Americans and employers agree that a top priority for President Trump and Congress should be lowering prescription drug costs. That was underscored this week with introduction of bipartisan legislation – the Fair Drug Pricing Act – a step in the direction of greater price transparency. The bill would require drug makers to justify their pricing and itemize their expenses before raising prices more than 10% in one year, or 25% over three years, on drugs that cost at least $100. (Remember the EpiPen controversy from last year?) Shortly after receipt of this pricing information, HHS would be required to make the data publicly available. In addition to providing a check on sharp price hikes, this could help PBMs and other drug purchasers make more informed decisions.
The Fair Drug Pricing Act mimics bills that have been introduced in more than a dozen state legislatures, and a growing number of state and federal lawmakers have offered a variety of proposals to address the issue. Congressional Democrats, for example, have proposed to allow Medicare to negotiate prices, remove tax breaks drug makers receive for advertising expenses, speed generic drugs to market, and allow Americans to import medicines from Canada, among other things.
The pharmaceutical industry opposes and will fight most of the proposals, but it’s clear that the industry and policymakers are feeling the heat over drug prices.
Go to full article: www.statnews.com